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72 Poster Session Iexpressed as AUC and outcome. Methods: All children, trans-
planted between 2001–2006, receiving intravenous BU as part
of a myeloablative regimen, from whom AUC measurements
were available, were included. Patients were separated into five
percentiles based on total AUC. The association with the primary
endpoints EFS (event defined as dead, graft-failure or relapse)
and survival as well as the secondary endpoints (acute Graft-ver-
sus-Host Disease grade 2–4; aGvHD, and Veno-occlusive Dis-
ease: VOD) were tested using uni- and multivariate Cox
regression analysis. The lowest AUC group was used as index
group. Results: 102 patients were included (46 malignant indica-
tions; 56 non-malignant indications). Median age at transplantation
was 3.1 years (range 0.2 to 21 years). The overall EFS and survival
were 68% and 72% respectively. In multivariate analyses a total
AUC between 72,500–80,000mgh/l was associated with highest
EFS (85%, p 5 0.029, table). Other factors influencing EFS were
HLA-disparity and age at SCT. Similar associations were found
for survival. aGvHD occurred in 16% of patients and was most fre-
quently seen in the highest AUC group 35% (p 5 0.041, table).
VOD was noted more frequent in the higher AUC, but not signif-
icant (p 5 0.164). The once daily dosing versus 4-times daily did
not influence any of the results. Above an AUC of 72.500 mgh/l,
no graft-failure was note and only 2 relapses (11%) were note.
While under 72.500 mgh/l, 9 graft-failure and relapses were seen
(31%).
In conclusion a total AUC between 72,500–80,000 mgh/l is as-
sociated with highest EFS in malignants as well as in non-malignant
disease. Higher AUC was associated with more toxicity negatively
influencing EFS, while lower AUC was associated with more re-
lapse/graft failure. Once daily dosing might be a practical alterna-
tive to 4-times daily. Dosing of busulfan in children should be
targeted by therapeutic drug monitoring to a small therapeutic
range to improve EFS.
Multivariate analysis of primary and secondary endpoint: EFS en GvHD
EFS GvHDP HR CI-95% P OR CI-95%AUC 0–55.000 1 1AUC 55,000–65,000 0.320 0.60 0.22–1.64 0.920 0.86 0.05–15.8AUC 65,000–72,500 0.537 0.72 0.25–2.05 0.330 3.41 0.29–40.2AUC 72,500–80,000 0.029 0.20 0.05–0.85 0.177 5.58 0.46–67.7AUC 80,000–120,000 0.378 0.59 0.18–1.92 0.041 12.55 1.10–143Malign vs
non-malignant0.080 5.13 0.82–31.9HLA disparity 0.001 3.79 1.72–8.35 0.197 0.38 0.09–1.65Melphalan 0.541 1.71 0.31–9.43Sero-therapy 0.244 2.42 0.55–10.7Age 0.001 1.12 1.05–1.19195
INFLUENCE OF DONOR AGE ON RISK OF CHRONIC GVHD IN SEX-MIS-
MATCHED PEDIATRIC ALLOGENIC HEMATOPOIETIC STEM CELL TRANS-
PLANT
Friedrich-Medina, P.M.2, Duncan, C.N.1, Lehmann, L.E.1. 1 Dana
Farber Cancer Institute/Children’s Hospital Boston, Boston, MA; 2 Chil-
dren’s Hospital Boston, Boston, MA.
Background: Donor age, donor/recipient sex mismatch, and do-
nor parity are considered to be significant risk factors for the devel-
opment of acute and chronic graft versus host disease. Most reports
indicate that female donors into male (F-M) recipients confer the
greatest risk. Female donor alloimmunization to minor histocom-
patibility antigens encoded by the Y-chromosome is thought to de-
velop through sexual exposure and/or parity and at least partially
explain the increased risk of GVHD seen in F-M transplants. There
are no studies that evaluate this association when a young female
serves as donor. Methods: Data from 43 male to male (M-M) and
38 female to male (F-M) sibling donor hematopoietic transplants
performed at our institution from 1998–2006 was collected and an-
alyzed. Twenty three F-M transplants used female donors less or
equal to 12 years old. Age range and mean age for each group wasas follows: M-M (1–23 years, 11 years), F-M with donor less than
or equal to 12 years old (0.2–16 years, 7 years), and F-M with donor
over 12 years old (9–33 years, 15 years). The majority of patients in
both groups had hematologic malignancies, was fully matched, and
received Cyclosporine and Methotrexate as GVHD prophylaxis.
Outcomes between patients with female donors less or equal to
12 years old were compared to those of patients with female donors
more than 12 years old, using patients with M-M transplant as base-
line. Only patients with aGVHD grade II-IV were included in anal-
ysis. Patients with death in the first 100 days were not included in
the cGVHD analysis.Results:As reported from adult literature, in-
creased risk of chronic GVHD (RR5 3.3, 95%CI5 1.47–7.38, p5
0.006) was observed in F-M transplant from older female donor
when compared to M-M (RR5 1). However, no significant increase
in risk of acute or chronic GVHD (RR5 0.76, p5 0.5; RR5 0.93,
p 5 0.9) was observed when the subgroup including young female
donors was compared to M-M (RR 5 1). Furthermore, no signifi-
cant difference in relapse or transplant related mortality rates in
the first 100 days were observed. Conclusion: This data suggests
that the increased risk for chronic GVHD observed in adult sex-
mismatched allogenic transplants may be related to donor alloim-
munity and may not be present when a young female serves as
donor.
Effect of donor-recipient sex match on Grade II-IV aGVHD, cGVHD,
Disease Relapse and Death in first 100 days
RR 95% CI P valueaGVHD
M-M (n 5 43) 11 1 NA NA
F-M (all combined) 10 1.02 0.60–1.72 0.93
F-M\12 (n 5 23) 4 0.76 0.29–1.78 0.5
F-M .13 (n 5 15) 6 1.61 0.68–3.82 0.29cGVHD
M-M (n 5 40) 4 1 NA NA
F-M (all combined) 8 1.52 0.93–2.48 0.14
F-M\12 (n 5 22) 2 0.93 0.28–3.05 0.9
F-M .13 (n 5 14) 6 3.3 1.47–7.38 0.006Relapse
M-M (n 5 43) 12 1 NA NA
F-M\12 (n 5 23) 4 0.65 0.26–1.65 0.34
F-M .13 (n 5 15) 4 0.95 0.35–2.57 0.92Death
M-M (n 5 43) 3 1 NA NA
F-M\12 (n 5 23) 1 0.7 0.12–3.97 0.7
F-M .13 (n 5 15) 1 0.92 0.16–5.58 0.97NA5 Not applicable.196
ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) IN UNRELATED CORD
BLOOD TRANSPLANTATION (UCBT): SINGLE INSTITUTION EXPERI-
ENCE, JULY 1996 – JUNE 2007
Alsultan, A., Giller, R.H., Bathurst, J., Hild, E., Kissane, B., Gore, L.,
Foreman, N.K., Keating, A., Quinones, R.R. The Children’s Hospital
and the University of Colorado School of Medicine, Aurora, CO.
UCBT has been associated with a lower incidence of GVHD
when compared to unrelated transplant using adult donors. How-
ever, the characteristics (sites, time to onset, course, and tolerability)
of GVH following UCBT has not been as clearly elucidated. We re-
view GVH in 81 consecutive UCBT treated on a single therapeutic
trial with consistenet GVH prophylaxis. 13 patients were unevalu-
able based on death prior to UCB infusion (2), death prior to en-
graftment (7), or graft rejection (4). Thus, 68 patients were
evaluable for AGVHD (41 male, 27 female; median age 6.8 yr
(range, 0.3–24.4 yr); median weight 22 Kg (range, 5.35–82.9 Kg)).
Diagnoses included leukemia in 75% (63% ALL, 25% AML,
12% CML or JMML), MDS 3%, lymphoma 1%, metabolic disor-
ders 6%, immune/genetic disorders 9%, and aplastic anemia 6%.
Acute leukemia disease status at UCBT was CR1 24%, CR2
Immune reconstitution in Artemis-deficient mice following allogeneic
mismatched HSCT
4 Wks Post HSCT 8 Wks Post HSCT
Marrow Prep
and Pre
Treatment (n) T Cells1 B Cells T Cells B Cells
HSC (5)2 0 0 N/A N/A
HSC/Anti-NK1.1(5) 0.20 ± 0.1 0.12 ± 0.1 0.51 ± 0.2 0.39 ± 0.2
HSC/PCT
sensitized
T cells (3)
0 0 N/A N/A
HSC/PCT
sensitized
T cells/Anti-NK1.1
(n 5 10 at 4 wks
and n 5 4 at 8 wks)
19.4 ± 11.8 22.4 ± 15.8 57.5 ± 26.7 30.7 ± 26.2
1Percent of CD31 T cells or CD45R/B2201 B cells in CD451
lymphocyte gate.
2
Poster Session I 7347%, CR3 or greater 18%, and not in remission in 11%. The me-
dian TNC infused was 4.06  10 7/kg (range, 0.73–28  10 7/kg),
median CD34 cells infused 2.3  10 5/kg (range, 0.3–31.7  10 5/
kg). HLA matching was 6/6 (23), 5/6 (31), and 4/6 (14). Condition-
ing was TBI-based in 66% and non-TBI in 34%. GVHD prophy-
laxis was cyclosporine and steroids in 91%, cyclosporine and
Methotrexate1/- steroids in 7%, and other in 2%. Median engraft-
ment times were 23.5 days for neutrophils and 65 days for platelets.
Acute GVHD had a median day of onset of 25 days (range, 10–93
days), with grade II-IV seen in 49% and grade III-IV in 25% of pa-
tients. The pattern of organ involvement with GVHD is shown in
the TableTable below. Isolated GI involvement was seen in 23%
of patients with grade III-IV acute GVHD. Event free survival at
1 and 2 yr were 62% and 58% for patients without acute GVHD,
75% and 56% for grade II only, and 53% and 47% for grade III-
IV acute GVHD. Survival with higher grade GVHD may be related
to both the more delayed onset of GVHD and more manageable
course of GVHD after UCBT.
Pattern of organs involved by acute GVHD
Organ system involved (%) HSC 5 lin- c-kit1 cells; 100,000 cells injected/animal.Acute GVHD
maximum gradeNo. of
patients Liver GI SkinGrade I 3 0 0 100%
Grade II 16 6% 50% 87%
Grade III 12 16% 100% 66%
Grade IV 5 80% 100% 100%
Total 36Table 1. HSCT details and outcome
Patient
Sex/Age (y)/
Diagnosis Graft
Nucleated
cell dose
108/Kg
Follow
up (mo)
ANC
500/platelets
50K/%donor GVHD Events/Lansky
1 F/12/thalassemia 8/8 BM MSD 2.2 53 17/103/97 No -/100
2 M/2/thalassemia 8/8 BM MSD 3.4 23 18/25/100 No -/100
3 M/0.8/thalassemia 8/8 BM MSD 5.8 8 11/22/61 No -/100
4 M/2.5/Sickle cell D 8/8 BM MSD 3.3 48 13/20/100 No -/100
5 F/9/Sickle cell D 5/6 UCB URD 0.42 22 (died) 16/-/100 chronic
extensive
GVHD, infection
6 M/15/Sickle cell D 8/8 BM MSD 2.31 13 12/65/100 chronic
limited
DLI for 53% donor
chimerism/100
7 F/17/SCD 6/8 BM URD 3.22 10 11/22/100 No Pneumatosis,
sz (resolved)/90
8 M/11/Sickle cell D 8/8 BM URD 6 9 16/19/97 grade 2
acute
hemolysis,
CMV/100
9 M/16/Sickle cell D 6/8 PB URD
T depleted
1.1 CD34 6 12/did
not drop/0
- graft rejection/
autologous
recovery
10 M/18/Sickle cell D 8/8 BM URD 4 1.5 13/14/97 grade 4 gut
(resolved)
GVHD/90197
PHOTOCHEMICALLY-TREATED (PCT) SENSITIZED CYTOTOXIC T CELLS
AND ANTI-NK1.1 ANTIBODY PRE-TREATMENT PROMOTE BOTH T
AND B CELL RECONSTITUTION IN NON-LEAKY ARTEMIS DEFICIENT
MICE WITH SEVERE COMBINED IMMUNODEFICIENCY DISEASE (SCID)
Xiao, Z., Dunn, E., Singh, K., Ibeid, R., Cowan, M.J. UCSF Children’s
Hospital, San Francisco, CA.
Artemis-deficiency results in T-B-NK1 SCID. It has a high in-
cidence in Athabascan-speaking Native Americans (SCIDA), and
is associated with increased sensitivity to alkylating agents and ion-
izing radiation. We previously reported a murine model of Artemis-
deficiency (mArt-/-) that unlike children with SCIDA, had a leaky
phenotype with some T cell numbers and function. We backcrossed
this mutation onto C57BL/6 (B6) mice and compared the pheno-
type to mArt-/- 129/SvJ ‘‘leaky’’ mice. We found that the %129/
SvJ in the background significantly correlated with increasing leak-
iness. B6 mArt-/- mice have virtually no leakiness based on pheno-
typing and function, comparable to SCIDA children. When
injected into 8 w/o mArt-/- recipients, we found that 1  105
Balb/c allomismatched lineage depleted and c-kit enriched (lin- c-
kit1) hematopoietic stem cells (HSC) were rejected (Table). Anti-
NK1.1 antibody pre-treatment resulted in limited engraftment.
We wanted to develop a non-chemotherapy based approach to pro-
moting engraftment. We generated Balb/c donor T cells sensitized
to B6 mice and treated them with Uvadex and UVA photochemical
therapy (PCT) which inhibits proliferation but not cytotoxic func-
tion. When 6  105 PCT sensitized Balb/c CD31 T cells were co-
injected with 1  105 Balb/c HSC into NK-reduced mArt-/- 8 wk
old mice, significant T and B cell reconstitution occurred by 4
wks post transplant with no evidence of GvHD at 8 wks (Table).
However, no engraftment appeared without anti-NK1.1 antibody
pre-treatment. These results indicate that both PCT sensitized
CD31 T cells and anti-NK1.1 antibody pre-treatment are neces-
sary to enhance the immune reconstitution following an allogeneic
HSCT. This non leaky Artemis-deficient mouse model more
closely resembles the phenotype seen in children with Artemis de-
ficiency including resistance to mismatched allogeneic cells and is
ideal for studying novel ways of correcting the immune deficiency
in SCID patients without using conditioning therapy with alkylat-
ing agents or ionizing radiation.198
ALLOGENEIC STEM CELL TRANSPLANTATION FOR CHILDRENWITH HE-
MOGLOBINOPATHY USING REDUCED INTENSITY CONDITIONING
Shenoy, S.1, DeBaun, M.1, Kamani, N.2, Adams, R.3, Grimley, M.4,
Wall, D.4, Gilman, A.5, Barnes, Y.1, Witty, S.1, Yu, L.6. 1 Washington
University School of Medicine, St. Louis, MO; 2 Children’s National
Medical Center, Washington DC; 3 Mayo Clinic, Phoenix, AZ; 4 Texas
Transplant Institute, San Antonio, TX; 5 UNC Lineberger Comprehen-
sive Cancer Center, Chapel Hill, NC; 6 Louisiana State University,
New Orleans, LA.
Background and Objective: Allogeneic hematopoietic stem cell
transplantation (HSCT) can establish normal red cell hematopoie-
sis and control hemoglobinopathy associated organ damage suc-
cessfully in children. However, HSCT is limited by donor
availability, conditioning related toxicities, and graft versus host dis-
ease (GVHD). Graft rejection rates are high especially after non-
myeloablative conditioning. HSCT is largely restricted to matched
sibling donor (MSD) transplants following myeloablative condi-
tioning. A multi-center trial using reduced intensity conditioning
(RIC) was developed for non-malignant disorders to decrease
